I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| extravillous trophoblast | 3 studies | 57% ± 6% | |
| placental villous trophoblast | 3 studies | 58% ± 23% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| extravillous trophoblast | 3 studies | 57% ± 6% | |
| placental villous trophoblast | 3 studies | 58% ± 23% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| placenta | 3 studies | 37% ± 18% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| adrenal gland | 100% | 76521.42 | 258 / 258 | 77% | 445.05 | 176 / 230 |
| ovary | 100% | 3193.13 | 180 / 180 | 68% | 3.67 | 292 / 430 |
| liver | 95% | 164.28 | 215 / 226 | 70% | 5.50 | 285 / 406 |
| breast | 98% | 177.16 | 450 / 459 | 30% | 4.19 | 340 / 1118 |
| brain | 92% | 163.12 | 2439 / 2642 | 34% | 0.90 | 238 / 705 |
| uterus | 97% | 166.77 | 165 / 170 | 27% | 1.53 | 126 / 459 |
| esophagus | 92% | 235.77 | 1328 / 1445 | 15% | 0.47 | 28 / 183 |
| prostate | 88% | 112.93 | 215 / 245 | 16% | 0.31 | 81 / 502 |
| ureter | 0% | 0 | 0 / 0 | 100% | 1.18 | 1 / 1 |
| spleen | 100% | 421.99 | 240 / 241 | 0% | 0 | 0 / 0 |
| lung | 71% | 62.02 | 411 / 578 | 28% | 1.76 | 323 / 1155 |
| adipose | 96% | 166.15 | 1155 / 1204 | 0% | 0 | 0 / 0 |
| bladder | 62% | 37.38 | 13 / 21 | 34% | 4.43 | 171 / 504 |
| muscle | 88% | 117.35 | 707 / 803 | 0% | 0 | 0 / 0 |
| kidney | 48% | 34.90 | 43 / 89 | 30% | 2.53 | 269 / 901 |
| stomach | 64% | 52.81 | 230 / 359 | 7% | 0.14 | 20 / 286 |
| eye | 0% | 0 | 0 / 0 | 69% | 2.51 | 55 / 80 |
| skin | 46% | 36.86 | 829 / 1809 | 21% | 2.93 | 100 / 472 |
| intestine | 61% | 52.17 | 593 / 966 | 5% | 0.14 | 27 / 527 |
| heart | 66% | 62.37 | 570 / 861 | 0% | 0 | 0 / 0 |
| thymus | 27% | 18.34 | 178 / 653 | 20% | 0.70 | 120 / 605 |
| tonsil | 0% | 0 | 0 / 0 | 40% | 2.53 | 18 / 45 |
| pancreas | 5% | 3.49 | 16 / 328 | 25% | 3.19 | 45 / 178 |
| peripheral blood | 16% | 21.17 | 151 / 929 | 0% | 0 | 0 / 0 |
| blood vessel | 13% | 15.09 | 174 / 1335 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0008203 | Biological process | cholesterol metabolic process |
| GO_0006704 | Biological process | glucocorticoid biosynthetic process |
| GO_0071375 | Biological process | cellular response to peptide hormone stimulus |
| GO_0016125 | Biological process | sterol metabolic process |
| GO_0034650 | Biological process | cortisol metabolic process |
| GO_0042359 | Biological process | vitamin D metabolic process |
| GO_0006700 | Biological process | C21-steroid hormone biosynthetic process |
| GO_0005759 | Cellular component | mitochondrial matrix |
| GO_0005743 | Cellular component | mitochondrial inner membrane |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0005506 | Molecular function | iron ion binding |
| GO_0008386 | Molecular function | cholesterol monooxygenase (side-chain-cleaving) activity |
| GO_0020037 | Molecular function | heme binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | CYP11A1 |
| Protein name | Cholesterol side-chain cleavage enzyme, mitochondrial (EC 1.14.15.6) (Cholesterol desmolase) Cholesterol side-chain cleavage enzyme, mitochondrial (EC 1.14.15.6) (CYPXIA1) (Cholesterol desmolase) (Cytochrome P450 11A1) (Cytochrome P450(scc)) Cytochrome P450 family 11 subfamily A member 1 Cytochrome P450 family 11 subfamily A polypeptide 1 Cytochrome P450 family 11 subfamily A polypeptide 1 isoform 3 |
| Synonyms | CYP11A |
| Description | FUNCTION: A cytochrome P450 monooxygenase that catalyzes the side-chain hydroxylation and cleavage of cholesterol to pregnenolone, the precursor of most steroid hormones . Catalyzes three sequential oxidation reactions of cholesterol, namely the hydroxylation at C22 followed with the hydroxylation at C20 to yield 20R,22R-hydroxycholesterol that is further cleaved between C20 and C22 to yield the C21-steroid pregnenolone and 4-methylpentanal . Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin) . . FUNCTION: A cytochrome P450 monooxygenase that catalyzes the side-chain hydroxylation and cleavage of cholesterol to pregnenolone, the precursor of most steroid hormones. Catalyzes three sequential oxidation reactions of cholesterol, namely the hydroxylation at C22 followed with the hydroxylation at C20 to yield 20R,22R-hydroxycholesterol that is further cleaved between C20 and C22 to yield the C21-steroid pregnenolone and 4-methylpentanal. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin). . FUNCTION: A cytochrome P450 monooxygenase that catalyzes the side-chain hydroxylation and cleavage of cholesterol to pregnenolone, the precursor of most steroid hormones. Catalyzes three sequential oxidation reactions of cholesterol, namely the hydroxylation at C22 followed with the hydroxylation at C20 to yield 20R,22R-hydroxycholesterol that is further cleaved between C20 and C22 to yield the C21-steroid pregnenolone and 4-methylpentanal. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin). . FUNCTION: A cytochrome P450 monooxygenase that catalyzes the side-chain hydroxylation and cleavage of cholesterol to pregnenolone, the precursor of most steroid hormones. Catalyzes three sequential oxidation reactions of cholesterol, namely the hydroxylation at C22 followed with the hydroxylation at C20 to yield 20R,22R-hydroxycholesterol that is further cleaved between C20 and C22 to yield the C21-steroid pregnenolone and 4-methylpentanal. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin). . FUNCTION: A cytochrome P450 monooxygenase that catalyzes the side-chain hydroxylation and cleavage of cholesterol to pregnenolone, the precursor of most steroid hormones. Catalyzes three sequential oxidation reactions of cholesterol, namely the hydroxylation at C22 followed with the hydroxylation at C20 to yield 20R,22R-hydroxycholesterol that is further cleaved between C20 and C22 to yield the C21-steroid pregnenolone and 4-methylpentanal. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin). . FUNCTION: A cytochrome P450 monooxygenase that catalyzes the side-chain hydroxylation and cleavage of cholesterol to pregnenolone, the precursor of most steroid hormones. Catalyzes three sequential oxidation reactions of cholesterol, namely the hydroxylation at C22 followed with the hydroxylation at C20 to yield 20R,22R-hydroxycholesterol that is further cleaved between C20 and C22 to yield the C21-steroid pregnenolone and 4-methylpentanal. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin). . FUNCTION: A cytochrome P450 monooxygenase that catalyzes the side-chain hydroxylation and cleavage of cholesterol to pregnenolone, the precursor of most steroid hormones. Catalyzes three sequential oxidation reactions of cholesterol, namely the hydroxylation at C22 followed with the hydroxylation at C20 to yield 20R,22R-hydroxycholesterol that is further cleaved between C20 and C22 to yield the C21-steroid pregnenolone and 4-methylpentanal. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin). . FUNCTION: A cytochrome P450 monooxygenase that catalyzes the side-chain hydroxylation and cleavage of cholesterol to pregnenolone, the precursor of most steroid hormones. Catalyzes three sequential oxidation reactions of cholesterol, namely the hydroxylation at C22 followed with the hydroxylation at C20 to yield 20R,22R-hydroxycholesterol that is further cleaved between C20 and C22 to yield the C21-steroid pregnenolone and 4-methylpentanal. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin). . |
| Accessions | ENST00000569662.1 Q2HZF3 C9JXV4 P05108 A0A0S2Z3M2 A0A0S2Z3H9 H3BSZ1 ENST00000450547.1 ENST00000268053.11 [P05108-1] ENST00000672385.1 [P05108-1] ENST00000416978.1 ENST00000566674.5 H3BS93 A0A0S2Z3R3 ENST00000435365.5 A0A0S2Z3T5 ENST00000358632.8 [P05108-2] C9JPU9 ENST00000672913.1 [P05108-2] E7EPP8 |
